Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Vaccines

  Free Subscription


Articles published in J Virol

Retrieve available abstracts of 90 articles:
HTML format



Single Articles


    November 2022
  1. STEPHENS LM, Ross KA, McLellan JS, Narasimhan B, et al
    Long-Lasting Protection Induced by a Polyanhydride Nanovaccine against Respiratory Syncytial Virus in an Outbred Mouse Model.
    J Virol. 2022;96:e0150222.
    PubMed     Abstract available


  2. HARWOOD OE, Balgeman AJ, Weaver AJ, Ellis-Connell AL, et al
    Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803.
    J Virol. 2022 Nov 15:e0142422. doi: 10.1128/jvi.01424.
    PubMed     Abstract available


    October 2022
  3. BRICE AM, Rozario AM, Rawlinson SM, David CT, et al
    Lyssavirus P Protein Isoforms Diverge Significantly in Subcellular Interactions Underlying Mechanisms of Interferon Antagonism.
    J Virol. 2022;96:e0139622.
    PubMed     Abstract available


  4. DING M, Dang W, Liu H, Zhang K, et al
    Sequential Deletions of Interferon Inhibitors MGF110-9L and MGF505-7R Result in Sterile Immunity against the Eurasia Strain of Africa Swine Fever.
    J Virol. 2022;96:e0119222.
    PubMed     Abstract available


  5. ELLIS-CONNELL AL, Balgeman AJ, Harwood OE, Moriarty RV, et al
    Control of Simian Immunodeficiency Virus Infection in Prophylactically Vaccinated, Antiretroviral Treatment-Naive Macaques Is Required for the Most Efficacious CD8 T Cell Response during Treatment with the Interleukin-15 Superagonist N-803.
    J Virol. 2022 Oct 3:e0118522. doi: 10.1128/jvi.01185.
    PubMed     Abstract available


  6. BONIFACIO JPPL, Williams N, Garnier L, Hugues S, et al
    Optimizing the Live Attenuated Influenza A Vaccine Backbone for High-Risk Patient Groups.
    J Virol. 2022 Oct 3:e0087122. doi: 10.1128/jvi.00871.
    PubMed     Abstract available


    September 2022
  7. CHABOT S, Gimie Y, Obeid K, Kim J, et al
    Enhanced In Vitro and In Vivo Potency of a T Cell Epitope in the Ebola Virus Glycoprotein Following Amino Acid Replacement at HLA-A*02:01 Binding Positions.
    J Virol. 2022;96:e0116621.
    PubMed     Abstract available


  8. REDDY VRAP, Nazki S, Brodrick AJ, Asfor A, et al
    Evaluating the Breadth of Neutralizing Antibody Responses Elicited by Infectious Bursal Disease Virus Genogroup A1 Strains Using a Novel Chicken B-Cell Rescue System and Neutralization Assay.
    J Virol. 2022;96:e0125522.
    PubMed     Abstract available


  9. DU Q, Yang X, Ma M, Zhang Q, et al
    The gC1qR Binding Site Mutant PCV2 Is a Potential Vaccine Strain That Does Not Impair Memory CD4(+) T-Cell Generation by Vaccines.
    J Virol. 2022 Sep 19:e0095922. doi: 10.1128/jvi.00959.
    PubMed     Abstract available


  10. SIA ZR, Chiem K, Huang WC, Seffouh A, et al
    Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus.
    J Virol. 2022 Sep 15:e0100622. doi: 10.1128/jvi.01006.
    PubMed     Abstract available


  11. AO Z, Ouyang MJ, Olukitibi TA, Warner B, et al
    A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    J Virol. 2022 Sep 7:e0133722. doi: 10.1128/jvi.01337.
    PubMed     Abstract available


    August 2022
  12. SHEN W, Wang Q, Wang Z, Liu M, et al
    Specific Monoclonal Antibodies Targeting Unique HA Epitopes Block H7N9 Influenza A Viral Replication.
    J Virol. 2022 Aug 29:e0123822. doi: 10.1128/jvi.01238.
    PubMed     Abstract available


  13. FILES JK, Sterrett S, Henostroza S, Fucile C, et al
    HLA-II-Associated HIV-1 Adaptation Decreases CD4(+) T-Cell Responses in HIV-1 Vaccine Recipients.
    J Virol. 2022 Aug 24:e0119122. doi: 10.1128/jvi.01191.
    PubMed     Abstract available


  14. NEERUKONDA SN, Wang R, Vassell R, Baha H, et al
    Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
    J Virol. 2022 Aug 24:e0114022. doi: 10.1128/jvi.01140.
    PubMed     Abstract available


  15. GUPTA SL, Mantus G, Manning KE, Ellis M, et al
    Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults.
    J Virol. 2022 Aug 17:e0058222. doi: 10.1128/jvi.00582.
    PubMed     Abstract available


  16. KEEP S, Stevenson-Leggett P, Dowgier G, Foldes K, et al
    A Temperature-Sensitive Recombinant of Avian Coronavirus Infectious Bronchitis Virus Provides Complete Protection against Homologous Challenge.
    J Virol. 2022 Aug 16:e0110022. doi: 10.1128/jvi.01100.
    PubMed     Abstract available


  17. SHI J, Zheng J, Tai W, Verma AK, et al
    A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    J Virol. 2022 Aug 16:e0011822. doi: 10.1128/jvi.00118.
    PubMed     Abstract available


  18. VERMILLION MS, Dearing J, Zhang Y, Adney DR, et al
    Animal Models of Enterovirus D68 Infection and Disease.
    J Virol. 2022;96:e0083322.
    PubMed     Abstract available


  19. DODANTENNA N, Ranathunga L, Chathuranga WAG, Weerawardhana A, et al
    African Swine Fever Virus EP364R and C129R Target Cyclic GMP-AMP To Inhibit the cGAS-STING Signaling Pathway.
    J Virol. 2022;96:e0102222.
    PubMed     Abstract available


  20. CHAN M, Tiwary M, Wu HL, Tailor N, et al
    Pandemic 1918 Influenza Virus Does Not Cause Lethal Infection in Rhesus or Cynomolgus Macaques.
    J Virol. 2022 Aug 4:e0072822. doi: 10.1128/jvi.00728.
    PubMed     Abstract available


  21. ABBADI N, Nagashima K, Pena-Briseno A, Ross TM, et al
    Differential Recognition of Computationally Optimized H3 Hemagglutinin Influenza Vaccine Candidates by Human Antibodies.
    J Virol. 2022 Aug 2:e0089622. doi: 10.1128/jvi.00896.
    PubMed     Abstract available


  22. YUAN M, Chen X, Zhu Y, Dong X, et al
    A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    J Virol. 2022 Aug 2:e0077522. doi: 10.1128/jvi.00775.
    PubMed     Abstract available


    July 2022
  23. DING M, Dang W, Liu H, Xu F, et al
    Combinational Deletions of MGF360-9L and MGF505-7R Attenuated Highly Virulent African Swine Fever Virus and Conferred Protection against Homologous Challenge.
    J Virol. 2022;96:e0032922.
    PubMed     Abstract available


  24. VUONO E, Ramirez-Medina E, Silva E, Rai A, et al
    Deletion of the H108R Gene Reduces Virulence of the Pandemic Eurasia Strain of African Swine Fever Virus with Surviving Animals Being Protected against Virulent Challenge.
    J Virol. 2022;96:e0054522.
    PubMed     Abstract available


  25. WANG M, Bohorquez JA, Munoz-Gonzalez S, Gerber M, et al
    Removal of the E(rns) RNase Activity and of the 3' Untranslated Region Polyuridine Insertion in a Low-Virulence Classical Swine Fever Virus Triggers a Cytokine Storm and Lethal Disease.
    J Virol. 2022;96:e0043822.
    PubMed     Abstract available


  26. PUSNIK J, Konig J, Mai K, Richter E, et al
    Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response.
    J Virol. 2022 Jul 12:e0076022. doi: 10.1128/jvi.00760.
    PubMed     Abstract available


  27. CHAPARIAN RR, Harding AT, Hamele CE, Riebe K, et al
    A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.
    J Virol. 2022 Jul 12:e0068922. doi: 10.1128/jvi.00689.
    PubMed     Abstract available


  28. RAMIREZ-MEDINA E, Vuono E, Silva E, Rai A, et al
    Evaluation of the Deletion of MGF110-5L-6L on Swine Virulence from the Pandemic Strain of African Swine Fever Virus and Use as a DIVA Marker in Vaccine Candidate ASFV-G-DeltaI177L.
    J Virol. 2022 Jul 11:e0059722. doi: 10.1128/jvi.00597.
    PubMed     Abstract available


  29. VAN DE VEN K, van Dijken H, Du W, de Heij F, et al
    Varying Viral Replication and Disease Profiles of H2N2 Influenza in Ferrets Is Associated with Virus Isolate and Inoculation Route.
    J Virol. 2022 Jul 11:e0073222. doi: 10.1128/jvi.00732.
    PubMed     Abstract available


    June 2022
  30. VAN OOSTEN L, Yan K, Rawle DJ, Le TT, et al
    An S1-Nanoparticle Vaccine Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice.
    J Virol. 2022 Jun 29:e0084422. doi: 10.1128/jvi.00844.
    PubMed    


  31. SHEWARD DJ, Hermanus T, Murrell B, Garrett N, et al
    HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies.
    J Virol. 2022 Jun 27:e0032422. doi: 10.1128/jvi.00324.
    PubMed     Abstract available


  32. KIM A, Lee G, Hwang JH, Park JH, et al
    BacMam Expressing Highly Glycosylated Porcine Interferon Alpha Induces Robust Antiviral and Adjuvant Effects against Foot-and-Mouth Disease Virus in Pigs.
    J Virol. 2022;96:e0052822.
    PubMed     Abstract available


  33. OLCZAK P, Matsui K, Wong M, Alvarez J, et al
    RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
    J Virol. 2022 Jun 15:e0056622. doi: 10.1128/jvi.00566.
    PubMed     Abstract available


  34. SUN C, Yuan RY, Xie C, Sun JF, et al
    Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines.
    J Virol. 2022 Jun 14:e0038322. doi: 10.1128/jvi.00383.
    PubMed     Abstract available


  35. LIN J, Law R, Korosec CS, Zhou C, et al
    Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity.
    J Virol. 2022 Jun 14:e0050922. doi: 10.1128/jvi.00509.
    PubMed     Abstract available


  36. CHEN X, Li J, Yang L, Zhou Y, et al
    Immunoglobin G Sero-Dynamics Aided Host Specific Linear Epitope Identification and Differentiation of Infected from Vaccinated Hosts.
    J Virol. 2022 Jun 6:e0014322. doi: 10.1128/jvi.00143.
    PubMed     Abstract available


    May 2022
  37. PRICE GE, Lo CY, Misplon JA, Epstein SL, et al
    Reduction of Influenza A Virus Transmission in Mice by a Universal Intranasal Vaccine Candidate is Long-Lasting and Does Not Require Antibodies.
    J Virol. 2022 May 31:e0032022. doi: 10.1128/jvi.00320.
    PubMed     Abstract available


  38. DELVA JL, Van Waesberghe C, Van Den Broeck W, Lamote JA, et al
    The Attenuated Pseudorabies Virus Vaccine Strain Bartha Hyperactivates Plasmacytoid Dendritic Cells by Generating Large Amounts of Cell-Free Virus in Infected Epithelial Cells.
    J Virol. 2022 May 23:e0219921. doi: 10.1128/jvi.02199.
    PubMed     Abstract available


  39. VANDOORN E, Stadejek W, Parys A, Chepkwony S, et al
    Pathobiology of an NS1-Truncated H3N2 Swine Influenza Virus Strain in Pigs.
    J Virol. 2022 May 12:e0051922. doi: 10.1128/jvi.00519.
    PubMed     Abstract available


  40. LINVILLE AC, Rico AB, Teague H, Binsted LE, et al
    Dysregulation of Cellular VRK1, BAF, and Innate Immune Signaling by the Vaccinia Virus B12 Pseudokinase.
    J Virol. 2022 May 11:e0039822. doi: 10.1128/jvi.00398.
    PubMed     Abstract available


  41. LUCAS CJ, Davenport BJ, Carpentier KS, Tinega AN, et al
    Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity.
    J Virol. 2022;96:e0006422.
    PubMed     Abstract available


  42. TU JJ, Kumar A, Giorgi EE, Eudailey J, et al
    Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.
    J Virol. 2022 May 10:e0023122. doi: 10.1128/jvi.00231.
    PubMed     Abstract available


    April 2022
  43. MANTLO EK, Maruyama J, Manning JT, Wanninger TG, et al
    Machupo Virus with Mutations in the Transmembrane Domain and Glycosylation Sites of the Glycoprotein Is Attenuated and Immunogenic in Animal Models of Bolivian Hemorrhagic Fever.
    J Virol. 2022;96:e0020922.
    PubMed     Abstract available


  44. KIRKPATRICK ROUBIDOUX E, Sano K, McMahon M, Carreno JM, et al
    Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies.
    J Virol. 2022 Apr 21:e0033222. doi: 10.1128/jvi.00332.
    PubMed     Abstract available


  45. NUNEZ CASTREJON AM, O'Rourke SM, Kauvar LM, DuBois RM, et al
    Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens.
    J Virol. 2022;96:e0220121.
    PubMed     Abstract available


  46. DESCHAMBAULT Y, Lynch J, Warner B, Tierney K, et al
    Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    J Virol. 2022 Apr 12:e0038922. doi: 10.1128/jvi.00389.
    PubMed     Abstract available


  47. TEMPLETON CW, Traktman P
    UV Irradiation of Vaccinia Virus-Infected Cells Impairs Cellular Functions, Introduces Lesions into the Viral Genome, and Uncovers Repair Capabilities for the Viral Replication Machinery.
    J Virol. 2022 Apr 11:e0213721. doi: 10.1128/jvi.02137.
    PubMed     Abstract available


  48. KONG XW, Zhang X, Bu GL, Xu HQ, et al
    Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
    J Virol. 2022 Apr 11:e0033622. doi: 10.1128/jvi.00336.
    PubMed     Abstract available


  49. BRIGGS K, Kirby C, Beavis AC, Zengel J, et al
    Immunogenicity of Mumps Virus Genotype G Vaccine Candidates in Jeryl Lynn-Immunized Mice.
    J Virol. 2022 Apr 7:e0198321. doi: 10.1128/jvi.01983.
    PubMed     Abstract available


  50. FARIAS JP, da Silva PS, Fogaca MMC, Santana IVR, et al
    The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine.
    J Virol. 2022 Apr 7:e0017722. doi: 10.1128/jvi.00177.
    PubMed     Abstract available


  51. KLASSE PJ, Moore JP
    Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.
    J Virol. 2022 Apr 6:e0003422. doi: 10.1128/jvi.00034.
    PubMed     Abstract available


    March 2022
  52. LIU MQ, Jiang RD, Guo J, Chen Y, et al
    Inactivated SARS-CoV-2 Vaccine Shows Cross-Protection against Bat SARS-Related Coronaviruses in Human ACE2 Transgenic Mice.
    J Virol. 2022 Mar 28:e0016922. doi: 10.1128/jvi.00169.
    PubMed     Abstract available


  53. NGUYEN HT, Qualizza A, Anang S, Zhao M, et al
    Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation.
    J Virol. 2022 Mar 28:e0166821. doi: 10.1128/jvi.01668.
    PubMed     Abstract available


  54. EICHHOLZ K, Tran TH, Cheneau C, Tran TTP, et al
    Adenovirus-alpha-Defensin Complexes Induce NLRP3-Associated Maturation of Human Phagocytes via Toll-Like Receptor 4 Engagement.
    J Virol. 2022;96:e0185021.
    PubMed     Abstract available


  55. RATHAKRISHNAN A, Connell S, Petrovan V, Moffat K, et al
    Differential Effect of Deleting Members of African Swine Fever Virus Multigene Families 360 and 505 from the Genotype II Georgia 2007/1 Isolate on Virus Replication, Virulence, and Induction of Protection.
    J Virol. 2022;96:e0189921.
    PubMed     Abstract available


  56. CHEN SMY, Wong YC, Yim LY, Zhang H, et al
    Enhanced Cross-Reactive and Polyfunctional Effector-Memory T Cell Responses by ICVAX-a Human PD1-Based Bivalent HIV-1 Gag-p41 Mosaic DNA Vaccine.
    J Virol. 2022 Mar 17:e0216121. doi: 10.1128/jvi.02161.
    PubMed     Abstract available


  57. ALLEN JD, Ross TM
    Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.
    J Virol. 2022 Mar 15:e0165221. doi: 10.1128/jvi.01652.
    PubMed     Abstract available


    February 2022
  58. ELSAYED H, Nabi G, McKinstry WJ, Khoo KK, et al
    Correction for Elsayed et al., "Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines".
    J Virol. 2022;96:e0195421.
    PubMed    


  59. UTRILLA-TRIGO S, Jimenez-Cabello L, Calvo-Pinilla E, Marin-Lopez A, et al
    The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge.
    J Virol. 2022;96:e0161421.
    PubMed     Abstract available


  60. ZHANG YN, Zhang ZR, Li N, Pei XR, et al
    High titer self-propagating capsidless Chikungunya virus generated in Vero cells as a strategy for alphavirus vaccine development.
    J Virol. 2022 Feb 2:JVI0148021. doi: 10.1128/JVI.01480.
    PubMed     Abstract available


  61. ROSU ME, Kok A, Bestebroer TM, de Meulder D, et al
    Contribution of neuraminidase to the efficacy of seasonal split influenza vaccines in the ferret model.
    J Virol. 2022 Feb 2:jvi0195921. doi: 10.1128/jvi.01959.
    PubMed     Abstract available


    January 2022
  62. LI Y, Yuan M, Han Y, Xie L, et al
    The Unique Glycosylation at Position 986 on the E2 Glycoprotein of Classical Swine Fever Virus Is Responsible for Viral Attenuation and Protection against Lethal Challenge.
    J Virol. 2022;96:e0176821.
    PubMed     Abstract available


  63. GMYREK GB, Predki P, Gershburg E, Carr DJJ, et al
    Noncognate Signals Drive Enhanced Effector CD8(+) T Cell Responses through an IFNAR1-Dependent Pathway after Infection with the Prototypic Vaccine, 0DeltaNLS, against Herpes Simplex Virus 1.
    J Virol. 2022 Jan 19:JVI0172421. doi: 10.1128/JVI.01724.
    PubMed     Abstract available


  64. KEEP S, Stevenson-Leggett P, Dowgier G, Everest H, et al
    Identification of amino acids within non-structural proteins 10 and 14 of the avian coronavirus infectious bronchitis virus that result in attenuation in vivo and in ovo.
    J Virol. 2022 Jan 19:jvi0205921. doi: 10.1128/jvi.02059.
    PubMed     Abstract available


  65. PETROVAN V, Rathakrishnan A, Islam M, Goatley LC, et al
    Role of African Swine Fever Virus Proteins EP153R and EP402R in Reducing Viral Persistence in Blood and Virulence in Pigs Infected with BeninDeltaDP148R.
    J Virol. 2022;96:e0134021.
    PubMed     Abstract available


  66. KIMBLE JB, Wymore Brand M, Kaplan BS, Gauger P, et al
    Vaccine-associated enhanced respiratory disease following influenza virus infection in ferrets recapitulates the model in pigs.
    J Virol. 2022 Jan 5:JVI0172521. doi: 10.1128/JVI.01725.
    PubMed     Abstract available


  67. MCGREGOR J, Hardy JM, Lay CS, Boo I, et al
    Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
    J Virol. 2022 Jan 5:JVI0167521. doi: 10.1128/JVI.01675.
    PubMed     Abstract available


    December 2021
  68. HUANG Y, Skarlupka AL, Jang H, Blas-Machado U, et al
    SARS-CoV-2 and Influenza A virus Co-infections in Ferrets.
    J Virol. 2021 Dec 22:JVI0179121. doi: 10.1128/JVI.01791.
    PubMed     Abstract available


  69. CAO K, Wang X, Peng H, Ding L, et al
    A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice.
    J Virol. 2021 Dec 15:JVI0157821. doi: 10.1128/JVI.01578.
    PubMed     Abstract available


  70. MUCKER EM, Golden JW, Hammerbeck CD, Kishimori JM, et al
    A nucleic acid-based orthopoxvirus vaccine targeting the vaccinia virus L1, A27, B5 and A33 proteins protects rabbits against lethal rabbitpox virus aerosol challenge.
    J Virol. 2021 Dec 1:JVI0150421. doi: 10.1128/JVI.01504.
    PubMed     Abstract available


    November 2021
  71. WU C, He Y, Zhao J, Luo K, et al
    Exacerbated AIDS progression by PD-1 blockade during therapeutic vaccination in chronically SIV-infected rhesus macaques after ART treatment interruption.
    J Virol. 2021 Nov 24:JVI0178521. doi: 10.1128/JVI.01785.
    PubMed     Abstract available


  72. APPELBERG S, John L, Pardi N, Vegvari A, et al
    Nucleoside-modified mRNA vaccines protect IFNAR(-/-) mice against Crimean Congo hemorrhagic fever virus infection.
    J Virol. 2021 Nov 24:JVI0156821. doi: 10.1128/JVI.01568.
    PubMed     Abstract available


  73. BURCKHARDT RM, Dennehy JJ, Poon LLM, Saif LJ, et al
    Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters.
    J Virol. 2021 Nov 24:JVI0197321. doi: 10.1128/JVI.01973.
    PubMed     Abstract available


  74. ZHANG H, Zheng H, Guo P, Hu L, et al
    Correction for Zhang et al., "Broadly Protective CD8(+) T Cell Immunity to Highly Conserved Epitopes Elicited by Heat Shock Protein gp96-Adjuvanted Influenza Monovalent Split Vaccine".
    J Virol. 2021;95:e0175021.
    PubMed    


  75. SOUZA CK, Anderson TK, Chang J, Venkatesh D, et al
    Antigenic distance between North American swine and human seasonal H3N2 influenza A viruses as an indication of zoonotic risk to humans.
    J Virol. 2021 Nov 10:JVI0137421. doi: 10.1128/JVI.01374.
    PubMed     Abstract available


  76. VANBLARGAN LA, Milutinovic PS, Goo L, DeMaso CR, et al
    Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.
    J Virol. 2021;95:e0095621.
    PubMed     Abstract available


  77. ZHANG Y, Ke J, Zhang J, Yang J, et al
    African Swine Fever Virus Bearing an I226R Gene Deletion Elicits Robust Immunity in Pigs to African Swine Fever.
    J Virol. 2021;95:e0119921.
    PubMed     Abstract available


  78. MIELKE D, Stanfield-Oakley S, Borate B, Fisher LH, et al
    Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies.
    J Virol. 2021 Nov 3:JVI0164321. doi: 10.1128/JVI.01643.
    PubMed     Abstract available


  79. CARTEN JD, Greseth M, Traktman P
    Structure-function analysis of two interacting vaccinia proteins that are critical for viral morphogenesis: L2 and A30.5.
    J Virol. 2021 Nov 3:JVI0157721. doi: 10.1128/JVI.01577.
    PubMed     Abstract available


    October 2021
  80. YU J, Collins ND, Mercado NB, McMahan K, et al
    Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques.
    J Virol. 2021 Oct 27:JVI0159921. doi: 10.1128/JVI.01599.
    PubMed     Abstract available


  81. SCHORCHT A, Cottrell CA, Pugach P, Ringe RP, et al
    The glycan hole area of HIV-1 envelope trimers contributes prominently to the induction of autologous neutralization.
    J Virol. 2021 Oct 20:JVI0155221. doi: 10.1128/JVI.01552.
    PubMed     Abstract available


  82. BELTRAN-PAVEZ C, Bontjer I, Gonzalez N, Pernas M, et al
    Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle (VLP) Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    J Virol. 2021 Oct 20:JVI0134321. doi: 10.1128/JVI.01343.
    PubMed     Abstract available


  83. GLADUE DP, Ramirez-Medina E, Vuono E, Silva E, et al
    Deletion of the A137R Gene from the Pandemic Strain of African Swine Fever Virus Attenuates the Strain and Offers Protection against the Virulent Pandemic Virus.
    J Virol. 2021;95:e0113921.
    PubMed     Abstract available


  84. GAO J, Klenow L, Parsons L, Malik T, et al
    Design of the Recombinant Influenza Neuraminidase Antigen is Crucial for its Biochemical Properties and Protective Efficacy.
    J Virol. 2021 Oct 6:JVI0116021. doi: 10.1128/JVI.01160.
    PubMed     Abstract available


  85. CHEN C, Zhang C, Li H, Wang Z, et al
    TLR4 regulates rabies virus-induced humoral immunity through recruitment of cDC2 to lymph organs.
    J Virol. 2021 Oct 6:JVI0082921. doi: 10.1128/JVI.00829.
    PubMed     Abstract available


    September 2021
  86. SIEGERS JY, Dhanasekaran V, Xie R, Deng YM, et al
    Genetic and Antigenic Characterization of an Influenza A(H3N2) Outbreak in Cambodia and the Greater Mekong Subregion during the COVID-19 Pandemic, 2020.
    J Virol. 2021 Sep 29:JVI0126721. doi: 10.1128/JVI.01267.
    PubMed     Abstract available


  87. CHOI A, Koch M, Wu K, Dixon G, et al
    Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants.
    J Virol. 2021 Sep 22:JVI0131321. doi: 10.1128/JVI.01313.
    PubMed     Abstract available


  88. KIRCHENBAUM GA, Sautto GA, Richardson RA, Ecker JW, et al
    A competitive hemagglutination inhibition assay for dissecting functional antibody activity to influenza virus.
    J Virol. 2021 Sep 15:JVI0237920. doi: 10.1128/JVI.02379.
    PubMed     Abstract available


    July 2021
  89. DONG H, Lu Y, Zhang Y, Mu S, et al
    A Heat-Induced Mutation on VP1 of Foot-and-Mouth Disease Virus Serotype O Enhanced Capsid Stability and Immunogenicity.
    J Virol. 2021;95:e0017721.
    PubMed     Abstract available


    June 2021
  90. VAN HAAREN MM, McCoy LE, Torres JL, Lee W, et al
    Antibodies from rabbits immunized with HIV-1 clade B SOSIP trimers can neutralize multiple clade B viruses by destabilizing the envelope glycoprotein.
    J Virol. 2021 Jun 2:JVI0009421. doi: 10.1128/JVI.00094.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: